CA2876916A1 - Kit for diagnosing malignant melanoma - Google Patents

Kit for diagnosing malignant melanoma Download PDF

Info

Publication number
CA2876916A1
CA2876916A1 CA2876916A CA2876916A CA2876916A1 CA 2876916 A1 CA2876916 A1 CA 2876916A1 CA 2876916 A CA2876916 A CA 2876916A CA 2876916 A CA2876916 A CA 2876916A CA 2876916 A1 CA2876916 A1 CA 2876916A1
Authority
CA
Canada
Prior art keywords
nite
antibody
group
gpc3
sparc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA2876916A
Other languages
English (en)
French (fr)
Inventor
Tetsuya Nakatsura
Keigo SAITO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Japan
LSIP LLC
Original Assignee
National Cancer Center Japan
LSIP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center Japan, LSIP LLC filed Critical National Cancer Center Japan
Publication of CA2876916A1 publication Critical patent/CA2876916A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2876916A 2012-06-18 2013-06-17 Kit for diagnosing malignant melanoma Withdrawn CA2876916A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012137019 2012-06-18
JP2012-137019 2012-06-18
PCT/JP2013/066631 WO2013191146A1 (ja) 2012-06-18 2013-06-17 悪性黒色腫（メラノーマ）の診断キット

Publications (1)

Publication Number Publication Date
CA2876916A1 true CA2876916A1 (en) 2013-12-27

Family

ID=49768742

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2876916A Withdrawn CA2876916A1 (en) 2012-06-18 2013-06-17 Kit for diagnosing malignant melanoma

Country Status (7)

Country Link
US (1) US9465030B2 (de)
EP (1) EP2863224A4 (de)
JP (1) JPWO2013191146A1 (de)
AU (1) AU2013278452A1 (de)
CA (1) CA2876916A1 (de)
TW (1) TW201403068A (de)
WO (1) WO2013191146A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
WO2015097928A1 (ja) * 2013-12-24 2015-07-02 中外製薬株式会社 可溶性ｇｐｃ３タンパク質の測定方法
CN106459959A (zh) 2014-05-08 2017-02-22 中外制药株式会社 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
CN108738347B (zh) * 2016-03-10 2022-01-14 国立癌症研究中心 辅助肝细胞癌患者的再发风险预测的方法、装置、计算机程序制品及试剂盒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6401754B1 (en) 2000-10-12 2002-06-11 Metso Automation Usa Inc. Four way valve
DE602004018819D1 (de) 2003-10-29 2009-02-12 Kumamoto Tech & Ind Found Diagnoseverfahren für malignes Melanom
AU2005297303B2 (en) * 2004-10-19 2011-11-10 Lsip, Llc Novel diagnostic kit for malignant melanoma

Also Published As

Publication number Publication date
JPWO2013191146A1 (ja) 2016-05-26
EP2863224A4 (de) 2016-05-04
AU2013278452A1 (en) 2015-01-29
US9465030B2 (en) 2016-10-11
WO2013191146A1 (ja) 2013-12-27
TW201403068A (zh) 2014-01-16
EP2863224A1 (de) 2015-04-22
US20150198598A1 (en) 2015-07-16
WO2013191146A9 (ja) 2014-04-17

Similar Documents

Publication Publication Date Title
JP5710699B2 (ja) オートタキシン測定による慢性肝疾患の検査方法および検査薬
JP5586368B2 (ja) 腫瘍マーカーとしてのｎ１，ｎ１２−ジアセチルスペルミン
US20210123917A1 (en) Method for examining liver cancer
US9465030B2 (en) Kit for diagnosing malignant melanoma
CN113248609B (zh) 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
JP2018080943A (ja) Ｎａｓｈの検出方法
WO2014192974A1 (ja) 抗ｌｇｒ６抗体を含む癌の検出用又は診断用試薬
JPWO2017159771A1 (ja) 肝細胞増殖因子（ｈｇｆ）のｐｄマーカー
KR20120116518A (ko) 폐암 조기 진단용 ＸＡＧＥ-1ａ 마커 및 이의 용도
EP3879270A1 (de) Verfahren zur erkennung von viralem leberkrebs
US11242408B2 (en) Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis
JP5553603B2 (ja) 新規肝癌マーカー
US11255856B2 (en) Immunoassay for detecting tumor pyruvate kinase M2
JP2012018119A (ja) 大腸癌検出用マーカーおよびそれを用いた大腸癌検出方法
JP2024070581A (ja) Ａｌｓ検査用バイオマーカー及び検査方法
JP2010139293A (ja) 早期癌腫瘍マーカー
JP5182684B2 (ja) カルボキシエチルアルギニンに対する抗体
WO2021056907A1 (zh) 杂交瘤细胞lcz9h4及其分泌的单克隆抗体和应用
JP2013234156A (ja) リンカー領域がリン酸化されたＳｍａｄ３を特異的に認識するモノクローナル抗体
WO2009090880A1 (ja) 糖尿病の診断方法
JPWO2017057622A1 (ja) 免疫測定用抗体とその作製方法

Legal Events

Date Code Title Description
AZWI Withdrawn application

Effective date: 20170118